文献速递血栓与止血贫血与红细胞疾病

JAK2V617F阳性缺血性脑血管病患者中额外CHIP突变的患病率及其影响

Prevalence and impact of additional CHIP mutations in JAK2V617F-positive ischaemic cerebrovascular patients.
PubMed 文献 · Br J Haematol · 2025-07-23

研究纳入591例缺血性脑血管病患者中的63例JAK2V617F阳性者和126例匹配对照,用靶向NGS检测体细胞突变。JAK2V617F阳性者额外体细胞突变更常见(47.6% vs 30.2%,p=0.028),VAF>10%的突变患病率更高(23.8% vs 7.9%,p=0.005)。

要点

  • JAK2V617F阳性缺血性脑血管病患者额外体细胞突变患病率为47.6%,高于对照的30.2%(p=0.028)。
  • JAK2V617F阳性者VAF>10%的其他突变患病率为23.8%,高于对照的7.9%(p=0.005)。
  • JAK2V617F阳性患者中,额外体细胞突变与更高的单核细胞水平相关(p=0.011)。

核心结论

  • JAK2V617F阳性的缺血性脑血管病患者更常携带其他体细胞突变且VAF更高,可能反映更进展的克隆谱,与JAK2V617F阳性个体的血管风险相关。

研究设计与样本

  • 从591例缺血性脑血管病患者队列中选取63例JAK2V617F阳性患者和126例匹配对照,用靶向二代测序(NGS)评估体细胞突变,并在部分患者中检测血清血栓炎症标志物。

主要发现

  • JAK2V617F阳性患者额外体细胞突变患病率为47.6%,高于对照的30.2%(p=0.028)。
  • JAK2V617F阳性患者VAF>10%的其他突变患病率为23.8%,高于对照的7.9%(p=0.005),该模式在JAK2V617F<1%的病例中持续存在(p=0.019)。
  • 在JAK2V617F阳性患者中,额外体细胞突变与更高的单核细胞水平相关,排除骨髓增殖性肿瘤患者后仍相关(p=0.011)。
  • 携带其他克隆性造血意义未明潜质突变的患者血管细胞黏附分子1(p=0.027)、可溶性尿激酶纤溶酶原激活物受体(p=0.010)和IL-10(p=0.045)更高,中性粒细胞与淋巴细胞比值也更高(p=0.002)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The JAK2V617F mutation is associated with increased cardiovascular risk, including ischaemic stroke. This study investigates the prevalence of additional mutations in ischaemic cerebrovascular patients with and without JAK2V617F to better understand the mechanisms contributing to thrombotic risk. We examined 63 patients with the JAK2V617F mutation and 126 matched controls from a cohort of 591 ischaemic cerebrovascular patients. Somatic mutations were assessed using targeted next-generation sequencing (NGS). Serum thromboinflammatory markers were evaluated in a subset of patients. Additional somatic mutations were more common in JAK2V617F-positive patients than in controls (47.6% vs. 30.2%, p = 0.028). Patients with JAK2V617F had a higher prevalence of other mutations with variant allele frequencies (VAFs) above 10% (23.8% vs. 7.9%, p = 0.005), a pattern that persisted in cases with JAK2V617F <1% (p = 0.019). In JAK2V617F-positive patients, additional somatic mutations were associated with higher monocyte levels, even when excluding myeloproliferative neoplasms patients (p = 0.011). Patients with other clonal haematopoiesis of indeterminate potential mutations exhibited higher vascular cell adhesion molecule 1 (p = 0.027), soluble urokinase plasminogen activator receptor (p = 0.010) and IL-10 (p = 0.045), as well as higher neutrophil to lymphocyte ratio (p = 0.002). Ischaemic cerebrovascular patients with the JAK2V617F mutation more frequently harbour other somatic mutations and at higher VAF. This may reflect a more advanced clonal profile with relevance for vascular risk in JAK2V617F-positive individuals.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Kristiansen MH, Skov V, Larsen MK, et al. Prevalence and impact of additional CHIP mutations in JAK2V617F-positive ischaemic cerebrovascular patients. Br J Haematol. 2025. PMID: 40701821. doi:10.1111/bjh.20242

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。